Vanguard Group’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-1,561,052
| Closed | -$52.8M | – | 4591 |
|
|
2021
Q2 | $52.8M | Sell |
1,561,052
-153,731
| -9% | -$3.92M | ﹤0.01% | 2347 |
|
|
2021
Q1 | $40.1M | Buy |
1,714,783
+6,419
| +0.4% | +$194K | ﹤0.01% | 2431 |
|
|
2020
Q4 | $49.2M | Sell |
1,708,364
-2,942
| -0.2% | -$74.1K | ﹤0.01% | 2207 |
|
|
2020
Q3 | $34.7M | Buy |
1,711,306
+35,193
| +2% | +$859K | ﹤0.01% | 2203 |
|
|
2020
Q2 | $50.4M | Buy |
1,676,113
+668,020
| +66% | +$24.1M | ﹤0.01% | 2011 |
|
|
2020
Q1 | $31.7M | Buy |
1,008,093
+56,007
| +6% | +$1.95M | ﹤0.01% | 2064 |
|
|
2019
Q4 | $44.9M | Buy |
952,086
+245,231
| +35% | +$7.08M | ﹤0.01% | 2169 |
|
|
2019
Q3 | $4.57M | Buy |
706,855
+176,524
| +33% | +$1.47M | ﹤0.01% | 3169 |
|
|
2019
Q2 | $6.51M | Buy |
530,331
+124,591
| +31% | +$1.39M | ﹤0.01% | 3075 |
|
|
2019
Q1 | $5.5M | Buy |
405,740
+345,913
| +578% | +$3.1M | ﹤0.01% | 3107 |
|
|
2018
Q4 | $240K | Sell |
59,827
-87,054
| -59% | -$525K | ﹤0.01% | 3869 |
|
|
2018
Q3 | $989K | Buy |
+146,881
| New | +$1.4M | ﹤0.01% | 3725 |
|
Vanguard Group's CNST Position: Q3 2021 in Review
Vanguard Group sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 1,561,052 shares — an estimated $52.8M sold.
Vanguard Group first reported a position in CNST in Q3 2018 and held it in 12 quarters. The position peaked at $52.8M in Q2 2021. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.
- Vanguard Group reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
- Vanguard Group sold 1,561,052 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $52.8M.
- Vanguard Group first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 12 quarters.
- Vanguard Group's Constellation Pharmaceuticals, Inc. position peaked at $52.8M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.
Based on Vanguard Group's 13F filing for Q3 2021, filed 12 Nov 2021.